Aptahem reports good safety profile for Apta-1 after concluded toxicology- and safety program (non-GLP)
Aptahem (publ) announce today that the final reports from the non-regulated GLP (Good Laboratory Practice) toxicology- and safety studies in Apta-1’s pre-clinical program show positive results. The results indicate that higher dosages of Apta-1, than previously estimated, shows a very good safety profile. The company is now preparing the next step in Apta-1's pre-clinical program, which includes regulatory GLP toxicology studies.The purpose was to ensure the maximum tolerated dose of Apta-1 as part of the regulatory-controlled pre-clinical safety program for the drug candidate Apta-1. The